Clinical trials: Hydroxychloroquine, completed
Rheumatoid Arthritis
Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)
The Swefot trial was designed to compare two treatment strategies for patients with early rheumatoid arthritis (less than 1 year symptom duration): the use of a combination of traditional antirheumatic medications (DMARDs)…
- Trial name
- SWEFOT (NCT00764725)
- Testing
- conventional DMARD combination, MTX plus anti-TNF
- Volunteers
- 487 people
- Sponsor
- Karolinska Institutet
IMMUNOTHERAPY
Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients
Out of 49 early-stage critically-ill COVID-19 patients, 21 patients are the experimental group who take convalescent plasma compared to 28 patients receive only conventional therapy without taking Convalescent plasma.
- Trial name
- NCT04441424
- Testing
- Convalescent plasma, Hydroxychloroquin with Azithromycin
- Where
- Iraq
- Volunteers
- 49 people
- Sponsor
- Alkarkh Health Directorate-Baghdad
Covid19
Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment
This study is a randomized, double-blinded, and placebo controlled phase III clinical trial which aims to investigate the superiority of hydroxychloroquine, favipiravir or hydroxychloroquine + favipiravir treatment, initiated…
- Trial name
- NCT04981379
- Testing
- Hydroxychloroquine, Favipiravir, Favipiravir + Hydroxychloroquine
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 1,120 people
- Sponsor
- Health Institutes of Turkey
Covid19, Musculoskeletal Abnormalities
Musculoskeletal Symptoms in Post Acute Covid-19 Patients
The patients whose musculoskeletal symptoms initiated or aggravated with Covid-19, were compared with the patients whose musculoskeletal symptoms did not change with Covid-19.
- Trial name
- NCT04932889
- Testing
- Survey, Laboratory parameters, chest computed tomography
- Where
- Turkey (Türkiye)
- Volunteers
- 280 people
- Sponsor
- Eskisehir City Hospital
Advanced BRAF Mutant Melanoma
Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
The primary purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with…
- Trial name
- BAMM (NCT02257424)
- Testing
- Trametinib 2 mg daily, hydroxychloroquine (HCQ), dabrafenib 150 mg orally twice a day
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Covid-19
A Preventive Treatment for Migrant Workers at High-risk of COVID-19
In December 2019, a novel coronavirus, now called COVID-19, emerged as a global health threat from Wuhan, China. Within weeks, the contagious virus spread within and between communities, causing a lower respiratory tract…
- Trial name
- NCT04446104
- Testing
- Hydroxychloroquine Sulfate Tablets, Ivermectin 3mg Tab, Zinc
- Where
- Singapore
- Volunteers
- 4,257 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore